High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia
- 22 December 2016
- journal article
- Published by American Society of Hematology in Blood
- Vol. 128 (25), 2931-2940
- https://doi.org/10.1182/blood-2016-04-712562
Abstract
Key Points The expression level of ROR1 on CLL cells varies between patients. High-level CLL-cell expression of ROR1 associates with more aggressive disease.Keywords
This publication has 36 references indexed in Scilit:
- The Tyrosine Kinase Receptor ROR1 Is Constitutively Phosphorylated in Chronic Lymphocytic Leukemia (CLL) CellsPLOS ONE, 2013
- The Onco-Embryonic Antigen ROR1 Is Expressed by a Variety of Human CancersThe American Journal of Pathology, 2012
- ROR1 Is Expressed in Human Breast Cancer and Associated with Enhanced Tumor-Cell GrowthPLOS ONE, 2012
- Immunophenotypic and gene expression analysis of monoclonal B-cell lymphocytosis shows biologic characteristics associated with good prognosis CLLLeukemia, 2011
- Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cellsBritish Journal of Haematology, 2010
- An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephaseBritish Journal of Haematology, 2008
- Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapyInternational Journal of Cancer, 2008
- Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5aProceedings of the National Academy of Sciences of the United States of America, 2008
- Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic featuresBlood, 2003
- Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic LeukemiaThe Journal of Experimental Medicine, 2001